touchPODCAST

touchPODCAST

By touchpodcastScience
Download on the App Store

touchPODCAST episodes

  • MDT and patient perspectives on real-world use of antihyperglycemic therapies to manage T2D and obesity

    touchMDT for touchENDOCRINOLOGY

    Listen to key experts from a multidisciplinary team and a patient discuss real-world use of antihyperglycemic therapies to achieve an effective combination of glycemic control, weight loss and cardiovascular benefits.

     The multidisciplinary team and patient

    • Diabetes nurse practitioner: Dr Shannon Idzik, USA
  • Primary care specialist: Professor Stewart Harris, Canada
  • Patient: Tammie Snowden, USA

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical education grant from Eli Lilly. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchendocrinologyime.org/antihyperglycemic-therapy-in-T2D-obesity-MDT-outlook//

    20 min
  • MDT and patient perspectives on antihyperglycemic therapies and their association with weight loss

    touchMDT for touchENDOCRINOLOGY

    Listen to key experts from a multidisciplinary team and a patient explore the importance of weight loss in T2D; GLP-1 RAs and SGLT2is and their association with weight loss; plus the patient’s experience of using a GLP-1 RA to manage their T2D and obesity. 

    The multidisciplinary team and patient

    • Endocrinologist: Professor Dr med Michael Nauck, Germany
  • Primary care specialist: Professor Stewart Harris, Canada
  • Patient: Tammie Snowden, USA

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical education grant from Eli Lilly. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchendocrinologyime.org/antihyperglycemic-therapy-in-T2D-obesity-MDT-outlook//

    17 min
  • Perspectives on the mechanism linking obesity with T2D

    touchMDT for touchENDOCRINOLOGY

    Listen to key experts from a multidisciplinary team discuss the mechanism linking obesity with T2D and share their observations from the clinic on the course of disease from obesity to T2D.

    The multidisciplinary team

    • Primary care specialist: Professor Stewart Harris, Canada
  • Endocrinologist: Professor Dr med Michael Nauck, Germany

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical education grant from Eli Lilly. This activity is provided by touchIME.

    For further information visit our website: https://touchendocrinologyime.org/antihyperglycemic-therapy-in-T2D-obesity-MDT-outlook//

     

    13 min
  • Frontline IO for advanced NSCLC: Updates from ASCO and ESMO 2021

    touchCONGRESS for touchRESPIRATORY

    Listen to Prof. Edward Garon (USA) cover key data presented at ASCO and ESMO 2021 on optimizing frontline immunotherapy for advanced NSCLC, including expert insights and interpretation from Dr Raffaele Califano (UK) and Prof. Anne-Marie Dingemans (The Netherlands).

    OVERVIEW

    • Data review with Prof. Garon (0:00)
  • Expert interview with Dr Califano, Prof. Dingemans and Prof. Garon, answering the questions below

    • INTERVIEW QUESTIONS

    1. Based on data recently presented at ASCO21 and ESMO 2021, how do you think new and emerging immunotherapy (IO) agents will impact the frontline treatment landscape in advanced NSCLC? (35:58)
  • How can key learnings from ASCO21 and ESMO 2021 be integrated into clinical practice when choosing between available IO-based regimens (e.g. IO monotherapy, IO combination therapy, and/or in addition to chemotherapy)? (43:28)
  • How is our understanding of the role of PD-L1 as a biomarker in NSCLC evolving in light of recent data, and what are the possible implications for clinical practice? (48:08)
  • What unmet needs remain surrounding biomarkers beyond PD-L1 in NSCLC, and what are the prospects for biomarker-driven individualized treatment decisions in future? (51:08)
  • What have the latest data, including patient-reported outcomes, taught us regarding the optimal management of patients receiving frontline immunotherapy for advanced NSCLC? (57:02)

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an unrestricted independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchrespiratoryime.org/optimizing-frontline-immunotherapy-for-advanced-nsclc/ 

    1 hr 3 min
  • Frontline IO for advanced NSCLC: Updates from ASCO and ESMO 2021

    touchCONGRESS for touchONCOLOGY

    Listen to Prof. Edward Garon (USA) cover key data presented at ASCO and ESMO 2021 on optimizing frontline immunotherapy for advanced NSCLC, including expert insights and interpretation from Dr Raffaele Califano (UK) and Prof. Anne-Marie Dingemans (The Netherlands).

    OVERVIEW

    • Data review with Prof. Garon (0:00)
  • Expert interview with Dr Califano, Prof. Dingemans and Prof. Garon, answering the questions below

    • INTERVIEW QUESTIONS

    1. Based on data recently presented at ASCO21 and ESMO 2021, how do you think new and emerging immunotherapy (IO) agents will impact the frontline treatment landscape in advanced NSCLC? (36:02)
  • How can key learnings from ASCO21 and ESMO 2021 be integrated into clinical practice when choosing between available IO-based regimens (e.g. IO monotherapy, IO combination therapy, and/or in addition to chemotherapy)? (43:32)
  • How is our understanding of the role of PD-L1 as a biomarker in NSCLC evolving in light of recent data, and what are the possible implications for clinical practice? (48:11)
  • What unmet needs remain surrounding biomarkers beyond PD-L1 in NSCLC, and what are the prospects for biomarker-driven individualized treatment decisions in future? (51:12)
  • What have the latest data, including patient-reported outcomes, taught us regarding the optimal management of patients receiving frontline immunotherapy for advanced NSCLC? (57:06)

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an unrestricted independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website:  https://touchoncologyime.org/optimizing-frontline-immunotherapy-for-advanced-nsclc/

    1 hr 3 min
  • Type 2 diabetes experts discuss achieving individualized glycemic targets in patients with T2D

    touchIN CONVERSATION for touchENDOCRINOLOGY

    Listen to Dr Vincent Woo in conversation with Dr Joanna Van. They respond to questions submitted by the HCP audience and provide their expert insights on the key considerations for achieving individualized glycemic targets in patients with type 2 diabetes.

    This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical educational grant from Eli Lilly. The activity is provided by touchIME.

    For further information visit our website:  https://touchendocrinologyime.org/achieving-individualized-glycemic-targets-in-T2D

    43 min
  • Investigating immunotherapies for endometrial cancer: Working as a MDT to identify patients and improve outcomes - Part 3

    touchMDT for touchONCOLOGY

    Listen to key experts from a multidisciplinary team discuss how patients with endometrial cancer should be tested to determine suitability for PD-1/PD-L1 inhibitor therapy.

    The multidisciplinary team

    • Gynaecological oncologist: Prof. Nicole Concin
  • Pathologist: Dr Alicia León-Castillo

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical education grant from GlaxoSmithKline. This activity is provided by touchIME.

    For further information visit our website: https://touchoncology.com/education/mdt-for-io-in-ec/

    14 min
  • Investigating immunotherapies for endometrial cancer: Working as a MDT to identify patients and improve outcomes - Part 2

    touchMDT for touchONCOLOGY

    Listen to key experts from a multidisciplinary team review a patient profile and describe how they would determine suitability for PD-1/PD-L1 inhibitor therapy.

    The multidisciplinary team

    • Gynaecological oncologist: Prof. Nicole Concin
  • Medical oncologist: Dr Antonio González-Martín
  • Pathologist: Dr Alicia León-Castillo

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical education grant from GlaxoSmithKline. This activity is provided by touchIME.

    For further information visit our website: https://touchoncology.com/education/mdt-for-io-in-ec/

    15 min
  • Investigating immunotherapies for endometrial cancer: Working as a MDT to identify patients and improve outcomes - Part 1

    touchMDT for touchONCOLOGY

    Listen to key experts from a multidisciplinary team discuss the latest data on PD-1/PD-L1 inhibitors and what they mean for patients with EC.

    The multidisciplinary team

    • Gynaecological oncologist: Prof. Nicole Concin
  • Medical oncologist: Dr Antonio González-Martín

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical education grant from GlaxoSmithKline. This activity is provided by touchIME.

    For further information visit our website: https://touchoncology.com/education/mdt-for-io-in-ec/

    14 min
  • Immunotherapy and evolving approaches for basal cell carcinoma

    touchEXPERT OPINIONS for touchIMMUNOLOGY

    Listen to leading experts discuss evolving treatment options for patients with advanced basal cell carcinoma, and how novel immunotherapeutic approaches within the emerging clinical study landscape may improve patient care.

    The experts

    • Prof. Axel Hauschild, University Hospital Schleswig-Holstein, Kiel, Germany
  • Dr Emily Ruiz, Brigham and Women’s Hospital, Boston, MA, USA
  • Prof. Ketty Peris, Catholic University of Rome, Rome, Italy

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical educational grant from Regeneron Pharmaceuticals, Inc. This activity is jointly provided by USF Health and touchIME.

    37 min

About touchPODCAST

From the publisher's feed

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites.